Abstract
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2021 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitioner. Lindsey Lyle, MS, PA-C, of University of Colorado Anschutz Medical Campus, considers promising results in the myeloid malignancies space. Ms. Lyle highlights long-term data on the combination of eprenetapopt (APR-246) and azacitidine in patients with TP53-mutated acute myeloid leukemia/myelodysplastic syndromes, a new option for patients with paroxysmal nocturnal hemoglobinuria, and valuable insights into Black and non-Black patient preferences regarding their treatment and communication with their providers.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
